Announcement on A Related-Party Transaction

3 September 2014

I. Overview

The Related-party Transaction Control Committee of the 6th session of the Board of Directors of the Company discussed and approved the Proposal on Granting Related-Party Credit to CSPC Pharmaceutical Group Limited, and consented to grant RMB13 billion one-year-term integrated credit lines (including those previously granted) to CSPC Pharmaceutical Group Limited. The credit lines include such credit types as short-term working capital loans, forfeiting (including basic style, derivative style and agency discounting), bank acceptance bills, financing L/G (with no longer than 2 years of term), wealth management products, issuance of spot and forward domestic L/C, buyer bill advance (under domestic L/C), standby L/C and import L/C (spot and forward), import bill advance under L/C, import bill advance under collection, T/T import bill advance, export bill advance under L/C, export bill advance under collection and packaged loans. The pricing of all financing interest rates and fees and charges shall be implemented in accordance with the policies of the Company and shall not be lower than 20%.

II. Withdrawal

The above transaction is a related-party transaction, and the related director withdrew from the relevant voting.

III. Impact

The above related-party transaction is a normal credit business of the Bank which has no material impact on the Company's business operations and financial condition.

VI. Opinion of the Independent Directors

The Company's granting of RMB13 billion integrated credit lines to CSPC Pharmaceutical Group Limited is a normal credit business of the Company, and the transaction plan complies with the general commercial provisions and the relevant rules and regulations promulgated by the regulatory authorities including the CBRC and the CSRC. The application and approval process comply with the rules and regulations under the Articles of Association and the Administrative Measures on Related-Party Transactions of the Company. The transaction is fair and no damage to lawful interest of other shareholders is identified.

Board of Directors China Minsheng Banking Corp., Ltd.